With a drug-treated population of more than 4 million people in the United States and EU5, the psoriasis market has been a lucrative space for drug developers, resulting in a plethora of approved agents with diverse mechanisms of action to treat the disease. In recent years, the dynamics of the psoriasis market have started to change; there has been a shift from the use of established TNF-α inhibitors as earlier-line agents to the earlier use of biologics like Stelara. More recently, the approval of IL-17 inhibitors such as Cosentyx and Taltz and IL-23 inhibitors such as Tremfya has resulted in increased pressure on these conventional agents for psoriasis. Nonetheless, the moderate to severe psoriasis early- and late-phase pipeline has several promising agents because drug developers realize that, despite multiple current treatments, an unmet need remains for novel agents that can differentiate themselves on the attributes of efficacy, delivery convenience, and catering to a broad patient population.
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Markets covered: United States, United Kingdom, France, Germany.
Primary research: Survey of 60 U.S. and 30 European dermatologists fielded in January 2019.
Key companies: AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Merck, Novartis.
Key drugs: Cosentyx, Enbrel, Humira, Otezla, Remicade, Stelara, Taltz, Tremfya.